Buscar
Mostrando ítems 11-20 de 7118
Tratamento do carcinoma metastático
(2004-04-01)
The renal cell carcinoma (RCC) is the seventh most common malignancy, accounting for more than 3% of cancer incidence in the United States. RCC is more common in males, occurring primarily in the 5 th to 7 th decades of ...
Drug-based cancer therapy to overcome immune resistance by steering tumor evolution
(Informa Healthcare, 2019-01)
We argue that therapy must lead rather than follow vis-à-vis cancer evolution. Clinical experience suggests that the evading phenotype resulting from treatment can never be fully anticipated or eliminated when a single ...
Emerging therapies in thoracic malignancies— immuno the rapy, targe ted the rapy, and t-cell the rapy in non–small cell lung cancer
Over the past decade there have been dramatic therapeutic advances for non–small
cell lung cancer (NSCLC) that have been based on an improved understanding of biomarkers, tumor immunology, driver mutations, T-cell receptors ...
Nanosystem functionalization strategies for prostate cancer treatment: a review
(2021-01-01)
Prostate cancer (PC) has a high morbidity and mortality rate worldwide, and the current clinical guidelines can vary depending on the stage of the disease. Drug delivery nanosystems (DDNs) can improve biopharmaceutical ...
Effects of photodynamic therapy mediated by emodin in cervical carcinoma cells
(2021-09-01)
Cervical cancer is a worldwide public health problem, and improved selective therapies and anticancer drugs are urgently needed. In recent years, emodin has attracted considerable attention due to its anti-inflammatory, ...
Therapy of primary liver cancer
Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide.
PLC is the leading cause of cancer-related deaths and the rate of incidence is predicted
to rise in the coming decades. PLC can be ...
Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses
(Informa Healthcare, 2019)